MIRA Q3 10-Q: Cash Falls to $2.5M, Going-Concern Doubt and Nasdaq Bid-Price Notice
MIRA sits 23% above its 52-week low of $0.51 on light trading volume (0.1× avg).
Summary
MIRA's Q3 2026 10-Q shows cash down to $2.5 million with substantial doubt about going concern, no ATM sales during the quarter, and a Nasdaq bid-price deficiency that must be cured by January 25, 2027.
Key Events · Earnings and Guidance · MIRA
-
Going-Concern Doubt Reiterated
Management states the company has insufficient cash to support operations for at least the 12 months following the filing and expects funds to last only into at least the first quarter of 2027.
-
Cash Burn Depletes Balance
Cash and equivalents fell to $2,504,631 at September 30, 2026 from $6,346,921 at December 31, 2025, after $3,705,874 used in operating activities over nine months.
-
No ATM Sales This Year
The company sold no shares under its ATM agreement during the three and nine months ended September 30, 2026, leaving up to $15,241,591 available under the December 5, 2025 supplement.
-
Nasdaq Bid-Price Deficiency
A July 27, 2026 Nasdaq notice flagged the stock below the $1.00 minimum bid; the company has until January 25, 2027 to regain compliance, potentially via a reverse stock split.
Analysis · MIRA · Life Sciences
MIRA ended September 30 with $2.5 million of cash, down from $6.3 million at year-end, after burning $3.7 million in operations over nine months. Management states plainly that cash is insufficient to fund operations for the next 12 months and only carries the company into at least the first quarter of 2027 — so a raise is required, and any equity financing would dilute holders at a share price already below $1. The Nasdaq minimum bid price notice received July 27, 2026 gives until January 25, 2027 to regain compliance, with a reverse split as the likely cure if the stock does not recover. Against that backdrop the pipeline news (Ketamir-2 Phase 2a targeted for Q2 2027, MIRA-55 and SKNY-1 in pre-IND work) is funded only if new capital arrives.
How filings like this one have moved
In the 30 days to Nov 15, 2026, 48.2% of the 1980 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.20%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, MIRA was trading at $0.63 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $26.5M. The 52-week trading range was $0.51 to $1.69. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.